Product Information

KEPPRA 250 MG TABLET is a brand product labeled by UCB, Inc., priced at $8.0786 per EA under NDC 50474059440. Its NADAC has been published 657 times since Nov 28, 2013.

FDA first approved this application on Nov 30, 1999. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the levetiracetam market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

KEPPRA 250 MG TABLET

levetiracetam
$8.0786per EA
High Outlier

Strength

250 mg/1

Manufacturer

UCB, Inc.

NDC

50474059440

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LEVETIRACETAM

Approval Type

New Drug (NDA)

FDA Application

NDA021035

FDA Approved

11/30/1999

TE Code

AB

On Market Since

4/24/2000

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for KEPPRA 250 MG TABLET has been published 657 times since Nov 28, 2013, and over the history we have for it it has risen 75.9%. The table below summarizes its recorded NADAC range and movement.

Current price$8.0786 per EA
All-time high$8.1159 (Jun 10, 2026)
All-time low$4.5935 (Nov 28, 2013)
52-week high$8.1159
52-week low$7.8990
Median price$6.3604
Average price$6.5250
Largest weekly change+9.9% (Jan 8, 2014)
Weeks tracked657
Tracking sinceNov 28, 2013

Price History

1W

+0.2%

1M

+0.2%

3M

-0.5%

6M

-0.5%

1Y

+2.1%

3Y

+9.3%

5Y

+23.8%

All

+75.9%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of KEPPRA 250 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for KEPPRA 250 MG TABLET, manufactured by UCB, Inc., is $8.0786 per EA (NDC 50474059440), effective Aug 19, 2026.

How has the price of KEPPRA 250 MG TABLET changed over time?

Over the history we have for it, the NADAC for KEPPRA 250 MG TABLET has risen 75.9%. It has been tracked across 657 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for KEPPRA 250 MG TABLET?

Since Nov 28, 2013, the NADAC for KEPPRA 250 MG TABLET has ranged from a low of $4.5935 (Nov 28, 2013) to a high of $8.1159 (Jun 10, 2026), with a median of $6.3604 per EA.

Are there cheaper alternatives to KEPPRA 250 MG TABLET?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as KEPPRA 250 MG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures KEPPRA 250 MG TABLET?

KEPPRA 250 MG TABLET (NDC 50474059440) is labeled by UCB, Inc., and CMS classifies it as a brand product.